About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Tuesday, December 12th, 2017

The QualityStocks
Daily Stock List


Osprey Gold Development Ltd. (OSSPF)

WatchDog Stocks, Stockhouse, InvestorsHub, Morningstar, MarketWatch, 4-Traders, OTC Markets, Junior Mining Network, Investing News, and Stock Orange reported on Osprey Gold Development Ltd. (OSSPF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Osprey Gold Development Ltd. centers on exploring five historically producing gold properties in the Province of Nova Scotia. Its flagship project is Goldenville, situated in the historical mining district Goldenville, which is one of eastern Canada’s most significant gold belts. The Company has the option to earn 100 percent (subject to certain royalties) in all five properties. This includes the Goldenville Gold Project. Osprey Gold Development has its corporate office in Vancouver, British Columbia.

The Goldenville Gold Project recorded greater than 212,300 ounces of gold production between 1862 and 1942. Goldenville has an updated NI
43-101 inferred resource that includes 2,800,000 tonnes at 3.20 g/t gold for a total of 288,000 ounces of gold (2.8 mil tonnes at 4.96 g/t gold for 447,000 ounces of gold uncapped).

Osprey Gold Development is also exploring the past producing Caribou, Lower Seal Harbour, Miller Lake, and Gold Lake gold projects. Osprey Gold entered into a definitive agreement whereby it has acquired an option to acquire the Caribou Gold Property from John Logan Enterprises Ltd. With this Option Agreement, Osprey Gold may acquire a 100 percent interest (subject to certain royalties) in 16 contiguous mining claims (256 hectares) hosting the past-producing Caribou Property.

The Caribou Gold property is 80 kilometers northwest of Halifax, Nova Scotia and 10 kilometers south of the rural community of Upper Musquodoboit, in Halifax County. The Caribou property contains an historic gold deposit that was intermittently mined between 1869 and 1955.

The Miller Lake Project is roughly 14 kilometers from Goldenville. It has historic production and limited recent exploration. The Gold Lake Project is about 70 kilometers northeast of Halifax. It was discovered in 1867 with minor production taking place in the late 1800’s.

The Lower Seal Harbour project is in Guysborough County, Nova Scotia. This property is around 35 kilometers from Goldenville. Gold at Lower Seal Harbour is found in the veins and the host rocks.

This past September, Osprey Gold announced that it completed the latest drilling program at its Goldenville Gold Project near Sherbrooke, Nova Scotia. The program was expanded from 2,500 meters to 3,044 meters. The expanded drill program included an additional hole at the Mitchell Lake prospect area, 4 kilometers to the east of the main Goldenville resource area, and added holes at the Goldenville resource area.

Recently, Osprey Gold announced that it completed surface work at the Lower Seal Harbour gold project near Goldboro, Nova Scotia. The Company’s initial program included geologic mapping, rock sampling, as well as mobile metal ion (MMI) soil geochemistry.

The program also included compilation and analysis of historic data with the objective of generating targets for future exploration and drill programs. A total of 121 samples from the earlier completed surface program were submitted for assay.

Osprey Gold Development Ltd. (OSSPF), closed Tuesday's trading session at $0.07886, down 5.44%, on 500 volume with 1 trade. The average volume for the last 60 days is 21,549 and the stock's 52-week low/high is $0.0601/$0.34.

International Western Petroleum, Inc. (INWP)

DreamTeamNetwork, Stock News Now, and Equities reported earlier on International Western Petroleum, Inc. (INWP), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

International Western Petroleum, Inc. is an E&P (Exploration & Production) company based in Irving, Texas. It specializes in the acquisition, development, and exploration of crude oil and natural gas properties in Texas. The Company is working to acquire oil and gas properties. In addition, it is working to apply the latest technologies and production techniques to boost acreage, productions, and reserves with an emphasis in the Central West Texas area. International Western Petroleum lists on the OTCQB.

The Company is concentrating on regional acquisition(s) with a focus in the Permian Basin region. International Western Petroleum’s area of interest is production locations within the Wolfcamp shale in the Midland Basin section of the Texas Permian Basin.

International Western Petroleum has acquired, from its operating partner International Western Oil Corp., Working Interests (WI’s) of two oil and gas production fields having proven reserves of roughly 154 Mbbl oil and 120 MMcf natural gas in Recoverable Net Reserves (PV10 report) in Coleman County, Texas.

The Company secured a number of concessions encompassing about 2,400 acres in the Central West Texas region. Outside the Central West Texas area and within the U.S., it has accessibility to roughly 95,000 acres of large-reserve oil and gas concessions, now under Company Management review for acquisition efforts.

International Western Petroleum is working with a technology company providing a state-of-the-art Organic Oil Recovery (OOR) process. This process can release trapped oil without exploration risks. Furthermore, International Western Petroleum has commenced initial field works in its own productions. This is while exploring this new technology, starting with the East Texas and Central West Texas areas.

International Western Petroleum has begun a new acquisition model based on the financed acquisition of mature oil fields that have major potential for the application of an Advanced Enhanced Oil Recovery (EOR) process, and also founded on strategic partnerships with existing operators to share production increases acquired via the implementation of this EOR process.

The Company has acquired a 3D Seismic leasehold in King County, Texas. This acquisition primarily includes a 350-acre leasehold in King County, with additional options to lease up to 800 acres of adjoining acreage with complete 3D seismic data.

International Western Petroleum completed an acquisition (in September of 2016) of a producing oil field in Kilgore, Texas, by way of the Marshall Walden Joint Venture (JV), a partnership with Odyssey Enterprises, LLC. International Western Petroleum is the managing venturer in the JV with Odyssey. There are 8 wellbores in the acquisition - 4 currently in production and 4 inactive.

The Company’s technology applications include Intelligent Fracking Technology With Petrophysics; Evolutionary Drilling Fluid Solutions; “Green” Enhanced Oil Recovery Technology; and State-Of-The-Art Stimulation Solution For Acidizing.

Regarding “Green” Enhanced Oil Recovery Technology, International Western Petroleum has identified a proven EOR technology, which has been applied to different environments in more than 40 oil fields in 4 continents with a 92 percent average increase in mature productions in greater than 300 well applications.

International Western Petroleum, Inc. (INWP), closed Tuesday's trading session at $0.25, down 3.85%, on 6,000 volume with 2 trades. The average volume for the last 60 days is 3,585 and the stock's 52-week low/high is $0.20/$1.50.

PeerLogix, Inc. (LOGX)

MarketWatch, InvestorsHub, Stockopedia, Marketwired, OTC Markets, Stockhouse, Barchart, The Street, DreamTeamNetwork, Business Insider, and Simply Wall St. reported on PeerLogix, Inc. (LOGX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

PeerLogix, Inc. is an advertising technology and data aggregation company listed on the OTC Markets’ OTCQB. PeerLogix provides a proprietary Software-as-a-Service (SAAS) platform that enables the tracking and cataloguing of over-the-top viewership and listenership. This is to determine consumer trends and preferences based upon media consumption. PeerLogix has its head office in New York, New York.

The Company’s focus is on delivering simple and flexible solutions its customers require to accurately recognize more consumers, define key audience segments, and manage customer acquisition and retention efforts. PeerLogix’s patent pending platform collects over-the-top data, including IP addresses of the streaming and downloading parties, the name, media type, and genre of media watched, listened or downloaded.

This platform uses licensed and publicly available demographic and other databases to further filter the collected data. This is to provide insights into consumer preferences to digital advertising firms, product and media companies, as well as entertainment studios and others.

The PeerLogix Real-Time Interaction System makes it easy for its clients to reach their customers who interact with their brand on numerous different channels at any time. Subsequently, the client can respond to their customers with contextually relevant messages that meet real-world needs.

Last month, PeerLogix announced a partnership with adsquare, the mobile-first data exchange, to provide PeerLogix data on adsquare's Audience Management Platform. The partnership will permit buyers in adsquare's Platform to buy PeerLogix's OTT engagement data comprising greater than 170 million households watching television programming, movies, or listening to music, globally.

adsquare is the mobile-first data exchange. It brings together advertisers and data providers in a fair, secure and privacy-friendly manner. The platform has been built mobile-first and operates in real-time. It allows advertisers to take advantage of data for audience targeting and precise moment marketing.

Today, PeerLogix announced select weekly estimates for the week ending December 10, 2017, as compiled by its proprietary measurement services. Annapurna’s “Detroit” was in first with a leading 329,000 hours streamed across all major and mid-major markets. Lionsgate Film’s Leatherface was in second with 290,000 hours streamed. Smith Global Media’s “Valley of Bones,” CJ Entertainment’s “Confidential Assignment” and Lionsgate Film’s “American Assassin,” rounded out the top five with 258, 195 and 172 thousand hours streamed, respectively.

PeerLogix is the established standard for tracking non-subscription based over-the-top viewership data of television, movies, and listeners of music worldwide.

PeerLogix, Inc. (LOGX), closed Tuesday's trading session at $0.07, up 5.58%, on 57,450 volume with 10 trades. The average volume for the last 60 days is 9,204 and the stock's 52-week low/high is $0.04/$0.24.

Tempus Applied Solutions Holdings, Inc. (TMPS)

InvestorsHub and MarketWatch reported on Tempus Applied Solutions Holdings, Inc. (TMPS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Tempus Applied Solutions Holdings, Inc. provides design, engineering, systems integration, and flight operations solutions. These support critical aviation mission requirements for an array of customers. The Company maintains a highly qualified and skilled in-house engineering team that supports aircraft modifications, certification, maintenance, and flight testing.

Tempus Applied Solutions, LLC is the wholly-owned subsidiary of Tempus Applied Solutions Holdings, Inc. Tempus Applied Solutions is based in Williamsburg, Virginia. The Company’s shares trade on the OTC Markets Group’s OTCQB.

Tempus flies airplanes - fixed wing and rotary, manned or unmanned. The Company engages in surveillance missions in Africa to flight training in Texas. Additionally, Tempus designs and modifies aircraft for special missions, certifies them, and provides turnkey lease and service solutions.

The Company operates Gulfstream, Bombardier, Pilatus, and Cessna aircraft. Most of these aircraft have been specially modified by Tempus for Department of Defense (DoD)-related missions. This includes threat simulation, surveillance, communications relay, as well as varied test and development programs.

The Tempus Design & Engineering Center of Excellence has Designated Engineering Representative (DER) authority from the Federal Aviation Administration (FAA) and the European Aviation Safety Agency (EASA). This center’s specialties include major airframe modifications; interior completions projects; design and materials specifications; modeling and rendering employing 3D Max Vision; Supplemental Type Certificates (STC); and Layout of Passenger Accommodations (LOPA) Development.

The Company’s Tempus Applied Solutions subsidiary was awarded FAA (Federal Aviation Administration) approval, in the form of a Supplemental Type Certificate (STC), for Tempus' initial FANS/1-A and ADS-B compliance solution [(Tempus' "Solution AA")]. Tempus' solution has received an "Approved Model List", or AML, STC. This means that it can be applied to any business and commercial aircraft. FANS and ADS-B compliance will be mandated in most parts of the world by 2020.

Tempus Applied Solutions utilizes a secure facility with hangar and manufacturing space and secure communications at Brunswick Executive Airport. The facility has two parallel 8000’ x 200’ runways and a 4.5-million-square-foot ramp and taxiways - certified for B-747, A-340, and C-5 aircraft.

In August 2017, Tempus Applied Solutions announced that it entered into a definitive purchase agreement for the acquisition of six Lockheed L-1011s formerly owned and operated by the Royal Air Force (RAF) of the United Kingdom (UK).  Four of these aircraft are specifically configured for air-to-air refueling (AAR) operations. The remaining two are configured for passenger and cargo operations only.

Tempus has in-house DER (Designated Engineering Representatives) capabilities encompassing 41 categories of aircraft systems. Capabilities include Part 23 Aircraft and Part 25 Aircraft as well as Repair Station DER. Moreover, authorities cover mechanical systems, electrical systems, and also flight testing.

Tempus Applied Solutions Holdings, Inc. (TMPS), closed Tuesday's trading session at $0.25, up 0.12%, on 30,196 volume with 13 trades. The average volume for the last 60 days is 85,324 and the stock's 52-week low/high is $0.03/$1.07.

Marina Biotech, Inc. (MRNA)

Zacks, MarketWatch, InvestorsHub, Stock Twits, The Street, MicroCap Daily, Street Insider, Barchart, YCharts, OTC Markets, Amigo Bulls, and Marketbeat reported on Marina Biotech, Inc. (MRNA), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

A biopharmaceutical enterprise, Marina Biotech, Inc. concentrates on the development and commercialization of unique therapeutics for hypertension, arthritis, pain, and oncology. The Company’s commercial product is Prestalia®. It is approved by the US FDA (Food and Drug Administration) for the treatment of hypertension. Prestalia® is being commercialized by way of the DyrctAxess platform. Marina Biotech is headquartered in City of Industry, California.

Marina Biotech is developing and commercializing late stage, non-addictive pain therapeutics. Its corporate mission is to provide effective and patient centric treatment for hypertension. This includes resistant hypertension. It is working to create a universal platform for the effective treatment of hypertension and for the distribution of fixed dose combination [FDC] hypertensive drugs such as Prestalia® and those in its pipeline.

Prestalia® contains perindopril arginine, an angiotensin converting enzyme inhibitor, and amlodipine, a dihydropyridine calcium channel blocker. Prestalia® is indicated for the treatment of hypertension, to lower blood pressure.

Prestalia® is available to physicians and patients via bpCareConnect. This is a hypertension management program offered by Symplmed. bpCareConnect (Powered by Symplmed’s DyrctAxess™ technology) is a patient membership program. This program caps blood pressure medication costs, provides monitoring devices, offers online tracking tools, and also ships directly to the patient.

Prestalia® may be used in patients whose blood pressure is not sufficiently controlled on monotherapy. Prestalia® may be used as initial therapy in patients likely to require multiple drugs to attain blood pressure goals.

In addition, Marina Biotech is developing and commercializing late stage, non-addictive pain therapeutics. The design of its ‘next-generation of celecoxib,’ including IT-102 and IT-103, are to control the dangerous side-effects of edema, which prohibit the drug from being prescribed at higher doses. These have the potential of replacing opioids and fighting the opioid epidemic. IT-102 and IT-103 are the Company’s next generation celecoxib for management of arthritis pain.

In late November, Marina Biotech announced the appointment of Mr. Isaac Blech to its Board, effective immediately. Mr. Blech is an experienced biotechnology entrepreneur and investor. He brings to Marina Biotech more than 35 years of expertise in the biotechnology industry.

Mr. Blech has founded and served on the Board of several companies. These companies have produced significant advances in a wide spectrum of diseases. These include the diagnosis of chlamydia, herpes, syphilis and HIV, and the treatment of cystic fibrosis, sexual dysfunction, multiple myeloma and many types of cancer and hematological disease.

Marina Biotech, Inc. (MRNA), closed Tuesday's trading session at $2.03, down 3.33%, on 2,723 volume with 13 trades. The average volume for the last 60 days is 4,051 and the stock's 52-week low/high is $1.21/$5.00.

Bagger Dave's Burger Tavern, Inc. (BDVB)

MarketWatch and The Street reported on Bagger Dave's Burger Tavern, Inc. (BDVB), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Bagger Dave's Burger Tavern, Inc. is the owner and operator of a full-service restaurant and bar, which has locations in Michigan, Ohio, and Indiana. Bagger Dave’s is a unique, ultra-casual restaurant and bar concept. It started operations in January 2008. The Company lists on the OTC Markets’ OTCQB. Bagger Dave's Burger Tavern is based in Traverse City, Michigan.

Bagger Dave’s Burger Tavern has the right to franchise the concept in Illinois, Indiana, Kentucky, Michigan, Missouri, Ohio and Wisconsin. The Company’s business strategy is to boost top and bottom line growth through the attainment of positive same-store-sales in comparable restaurant locations, and also the successful implementation of cost cutting initiatives at the restaurant and support level.

At present, Bagger Dave’s Burger Tavern operates 19 Bagger Dave’s restaurants - 16 located in Michigan, one in Indiana, and two in Ohio. The Company specializes in locally-sourced, never-frozen, prime rib recipe burgers, all-natural lean turkey burgers, hand-cut fries, locally crafted beers on draft, hand-dipped milk shakes, salads, black bean turkey chili, and more.

The Bagger Dave concept differentiates itself from other full-service casual dining establishments via the absence of walk-in freezers and microwaves. This validates the Company’s fresh food offerings.

Bagger Dave Burgers include the Santa Fe Chipotle Turkey Burger; the Asian Turkey Burger; the Mushroom & Swiss Turkey Stack; the Fiery Bleu Buffalo Turkey Burger; the Black Bean Veggie Burger; and the Blackened Mahi-Mahi Burger and more. In addition, Bagger Dave’s offers its “Create Your Own Burger” option. Its burgers are chef created.

Bagger Dave Sandwiches include Bagger’s Backyard BBQ Chicken Sandwich; the Tuscan Grilled Chicken Sandwich; the Grilled Chicken Parm Sandwich; Sloppy Dave’s® Sandwich; Awesome Grilled Cheese; the Egg, Bacon and Cheddar; and the California BLT. Sides include Cajun Sea Salt Tortilla Chips; Smokin’ Hot Mac ‘N’ Cheese Side; and Turkey Black Bean Chili Side, among others.

Restaurateur Mr. Michael Ansley created Bagger Dave's Burger Tavern in 2008. Mr. Ansley and his team opened the first location in Berkley, Michigan. They subsequently continued successful openings across Michigan, Indiana, and Ohio. The Company’s burger tavern is named in memory of Michael’s father-in-law, Dave.

Bagger Dave's Burger Tavern, Inc. (BDVB), closed Tuesday's trading session at $0.058, down 3.01%, on 35,907 volume with 9 trades. The average volume for the last 60 days is 62,150 and the stock's 52-week low/high is $0.026/$0.75.

HealthLynked Corp. (HLYK)

InvestorsHub and OTC Markets reported on HealthLynked Corp. (HLYK), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, HealthLynked Corp. focuses on improving healthcare services for patients and physicians. The Company’s technology cuts wait times with online scheduling of appointments and real-time appointments by local providers. Its technology also provides easy access to an individual’s and their family's updated medical records. HealthLynked is headquartered in Naples, Florida. The Company commenced trading on the OTC Markets Group’s OTCQB in May 2017.

HealthLynked centers on improving healthcare through connecting patients with their healthcare providers. The HealthLynked Network focuses on the efficient, secure exchange of medical information between patients and their healthcare providers.

The cloud-based HealthLynked Network lets patient's medical records move with them. This is so one’s medical records are not fragmented in manifold healthcare systems and/or EHR systems.

HealthLynked profile information safeguards that doctors don't prescribe potentially harmful medications in case a patient forgets to mention one or more present medications while talking to their doctor. Moreover, the HealthLynked Healthcare Summary page allows patients to keep their medical records updated. This helps physicians to be more productive and provide valid medical care.

Healthcare experts can easily be in touch with patients. They can provide their advice in case of emergencies via the Telemedicine Portal. The HealthLynked Healthcare Summary permits patients to maintain a complete medical profile in coordination with physicians. All information is systematically categorized. As a result, physicians have a total overview of patient health without them having to fill unnecessary paperwork.

This past September, HealthLynked announced it has created more than 880,000 HealthLynked Provider base profiles for every physician in the United States. The creation of the HealthLynked provider network is a vital step in allowing the Company’s patient members to search, geo-locate, and ultimately "Lynk" to any healthcare provider anywhere in the U.S.

Last month, HealthLynked announced its Q3 2017 financial results. It reported revenue of $480,723, and an operating loss of $512,153, which included roughly $135,500 of legal, accounting and other expenses related to the Company’s continuing public filings and investor relations cost and about $158,500 of incremental salary, benefits and other costs related to investment in initial sales and marketing efforts, and software development of the HealthLynked Network.

This was offset by a decrease in Naples Women’s Center’s general and administrative expenses of roughly $45,000, versus Q3 of 2016. The results compare with revenue of $516,798 and an operating loss of $482,570 in Q2 of 2016.

HealthLynked Corp. (HLYK), closed Tuesday's trading session at $0.08, even for the day. The average volume for the last 60 days is 14,119 and the stock's 52-week low/high is $0.07/$0.90.


The QualityStocks
Company Corner



The QualityStocks Daily Newsletter would like to spotlight ABcann Global (ABCCF). Today, ABcann Global closed trading at $1.2714, up 14.54%, on 608,459 volume with 508 trades. The stock’s average daily volume over the past 60 days is 432,739 and its 52-week low/high is $0.6171/$1.42.

ABcann Global (TSX.V:ABCN) (OTCQB:ABCCF) is pleased to announce that it has entered into a binding letter of intent dated December 11, 2017 (the “LOI”) to acquire (the “Acquisition”) all of the outstanding securities of Harvest Medicine Inc. (“HMED” or “Harvest Medicine”). This transaction unites the high-quality, precision growing focus of ABcann with the high-quality, customized patient focus of HMED. As Canada’s fastest growing medical cannabis clinic, Harvest Medicine has educated and serviced over 8,500 active patients since opening in February 2017.

ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF) ABcann Medicinals, Inc. is a globally licensed, cost efficient producer of premium quality organic standardized medicinal cannabis. One of the earliest licensed Canadian medical marijuana producers under Canada's federally-controlled Access to Cannabis for Medical Purposes Regulations (ACMPR), ABcann has five years of operating experience in the burgeoning medical marijuana space. The company currently owns and operates a fully functioning 14,500 square foot facility in Napanee, Ontario. Additionally, ABcann owns 65 acres of real estate with proper zoning and existing infrastructure in place to support the construction of another production facility of up to one million square feet.

In a November 2016 report, market research firm Canaccord Genuity Group forecasted that the medical marijuana market in Canada could see sales in excess of $8 billion by 2024, creating a sizable opportunity for the country's licensed producers (LPs). The research firm also noted that the "rigorous process of becoming a licensed producer of cannabis in Canada imposes significant barriers to entry and there will be a shortfall of supply in a legalized market in the short-term." This market barrier serves as a strategic advantage for ABcann as it prepares for its highly-anticipated IPO, which is currently scheduled for April 2017.

Canaccord's synopsis of the Canadian cannabis industry is supported by recent market activity, as companies sporting one of the illustrious Canadian government licenses for medicinal production have recorded strong growth following IPO. Canopy Growth (OTC: TWMJ), one of the largest fully-licensed Canadian marijuana growers, saw share prices skyrocket by more than 700 percent in the months following its initial offering. Aphria Inc. (OTC: APHQF), another licensed grower, climbed by more than 900 percent following its IPO. Other companies that have recorded huge growth since going public include Aurora Cannabis (OTC: ACBFF), climbing nearly 900 percent, and SupremePharma (OTC: SPRWF), which soared more than 1,300 percent.

With these market trends in mind, ABcann's impending IPO is one that prospective investors in the marijuana sector will want to explore. Recalls from some of the biggest players in the Canadian cannabis industry have highlighted the considerable learning curve that LPs face in today's market, which makes ABcann's proven track record in the market all the more noteworthy. The company has built a reputation over the years for its best-in-class standardized approach to growing cannabis, including the thoughtful omission of pesticides and a computer monitored growing technique that allows ABcann to minimize the risks of variance in its yields and ensure the creation of consistently high-quality products.

This technique, which the company calls the ABcann Advantage, has helped it record a customer retention rate of 94.7 percent alongside 30 percent month-over-month customer growth. When combined with ABcann's current yield rate, which it has measured at roughly 100 percent greater than the industry average, the company has constructed a strong foundation upon which to build a sizable presence in the global cannabis industry. This global growth potential is illustrated by ABcann's partnership with Israel's Syqe Medical, producer of the world's first selective-dose pharmaceutical grade medicinal plant inhaler. After visiting the company's production facility, Perry Davidson, founder of Syqe Medical, noted that ABcann's production technologies put it "in a class with the best in the world" in its ability to produce standardized pharmaceutical grade cannabis.

ABcann's entry into the public sector is being guided by a seasoned management team, board of directors and advisory board that feature well over a century of combined industry experience. Ken Clement, the company' founder and executive chairman, has been the key component and driving force behind ABcann's development since its inception. His vision of standardized production and dosage sets ABcann apart in the medical cannabis sector. Clement is joined on the company's management team by CEO Aaron Keay. Keay brings more than a decade of capital markets experience to ABcann, having played a role in raising approximately $250 million for public and private market issuers.

Notably, ABcann also has access to the 'Father of Cannabis Research', Raphael Mechoulam, PhD, through its board of advisors. An organic chemist and professor of medicinal chemistry at the Hebrew University of Jerusalem, Mechoulam was the first scientist to isolate both cannabidiol (CBD) and tetrahydrocannabinol (THC), and he has received more than 25 prestigious academic awards, including the Rothschild Prize in Chemical Sciences and Physical Sciences in 2012.

With more than 65 acres of growth capacity, a healthy cash balance to fund upcoming construction efforts, steady sales growth, industry-leading yield rates and an established operations team in place, ABcann is well-positioned to compete in the rapidly-expanding Canadian medicinal cannabis industry. These factors, along with the company's ongoing global expansion into the European, Australian and Israeli markets, show why ABcann Medicinals' upcoming public offering fits the bill as "Canada's Next Medical Marijuana IPO." Disclaimer

ABcann Global Blog

ABcann Global News:

ABcann Enters into Agreement to Acquire Leading Medical Cannabis Clinic

ABcann Global Announces Financial Results and Provides Operational Update

NetworkNewsWire Announces Publication on Investment Capital Pouring into Canada's Legal Cannabis Market

Singlepoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight Singlepoint, Inc. (SING). Today, Singlepoint, Inc. closed trading at $0.09952, off by 1.47%, on 14,295,554 volume with 1,224 trades. The stock’s average daily volume over the past 60 days is 8,657,130, and its 52-week low/high is $0.01/$0.415.

SinglePoint, Inc. (OTC:SING) today announces key advances in its corporate mission with the launch of additional joint ventures and the closing of new deals within existing agreements. SinglePoint has achieved considerable growth in 2017, and management today also provides a recap of achievements over the last year, as well as details key initiatives for 2018.

Singlepoint, Inc. (SING) has grown from a full-service mobile technology provider to a publicly-traded holding company. Through diversification into horizontal markets, SinglePoint is building its portfolio by acquiring an interest in undervalued subsidiaries, thereby providing a rich, diversified holding base.

SinglePoint's approach is to first research and identify acquisition opportunities in which it can take an active and influential role among existing leadership to provide enhanced strategy and direction. Target companies are undervalued, cash-flow positive, with high potential and verified assets. SinglePoint acquires and takes controlling interest of successful candidate companies.

SinglePoint recently signed a Letter of Intent to acquire an interest in Jacksam Corp., dba Convectium, a profitable California-based provider of equipment, branding, and packaging solutions for the cannabis industry. Convectium has developed the world's first cartridge and vape pen oil filling machine for wholesale distribution to dispensaries. The 710Shark and 710Seal systems can fill and package over 100 cartridges or disposable vape pens in 30 seconds and are sold to dispensaries through its EquipCanna.com brand. The company also operates a consumer brand that includes BlackoutX and HazeSticks and reaches customers in over 52 countries.

Additionally, SinglePoint has raised more than $300,000 and has signed a Letter of Intent to secure an additional $1 million in funding. The move provides management with ample capital to execute its business plan, while avoiding debt repayments that can eat into cash flow and reduce flexibility over time. It's also a rare development for a development-stage company in the cannabis industry.

Guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital, SinglePoint continues to explore high-potential acquisition opportunities to grow and diversify its current holding base. The company also plans to uplist to the OTCQB and become a fully reporting company during the current fiscal year.

The company has engaged Milost Advisors to pursue acquisitions and financing facilities toward funding acquisitions, as well as to provide working capital. Milost Advisors will assist SinglePoint in the acquisition of undervalued companies with annual revenues of at least $50 million, and has already identified potential acquisition targets for the company to consider. Disclaimer

Singlepoint, Inc. Company Blog

Singlepoint, Inc. News:

SinglePoint Expands Roster of Strategic Agreements and Joint Ventures, Covers Upcoming Key Initiatives in Recap of a Successful 2017

Smart Cannabis Corp and SinglePoint, Inc. Announce Joint Venture Expanding Blockchain Technology into SMARTAPP Automation Software for the Rapidly Growing Cannabis Market

SinglePoint and Smart Cannabis Corp. Sign Joint Venture to Integrate, Distribute ‘SMART APP’ for Cannabis Businesses

PotNetwork Holdings Inc. (POTN)

The QualityStocks Daily Newsletter would like to spotlight PotNetwork Holdings Inc. (POTN). Today, PotNetwork Holdings Inc. closed trading at $0.0648, up 11.92%, on 8,484,891 volume with 537 trades. The stock’s average daily volume over the past 60 days is 3,208,106, and its 52-week low/high is $0.002/$0.0995.

PotNetwork Holding, Inc. (OTC Pink: POTN) today announces that the first segment of its auditing requirement has been completed, with 2017’s audit well underway. East West Accounting Services, LLC has satisfied compliance parameters, and expects to have the full audit completed by the second week in January. The Company has taken this action as an initial step in its strategy to advance to the OTCQB, and long-term goal of achieving a NASDQ Capital Market listing.

PotNetwork Holdings Inc. (POTN), based in Fort Lauderdale, Florida, is a holding company. The company's First Capital Venture Co. subsidiary is the owner of Diamond CBD, Inc., a producer of widely-distributed CBD hemp extracts and the primary operating entity of PotNetwork Holdings.

Diamond CBD is made up of chemists and other scientists focused on developing and producing very high-quality CBD oil over a broad range of products, based upon a thorough understanding of the various natural molecules found in hemp and their particular properties. All products are made with federally legal cannabidiol (CBD), and are available in hundreds of flavors and sizes. The company emphasizes a dedication to 100% natural lab-tested CBD ingredients, with a carefully monitored process all the way from the source farm, through production, and final delivery to retail shelves.

PotNetwork, through Diamond CBD, delivers products to all 50 states, as well as internationally, and controls 15 CBD brands. The company lists the following product brands:

  • Diamond CBD Gummies - Diamond CBD branded edible gummies made from crystal isolate. Available in a variety of flavors and gummy styles, including rainbow bites, mini fruit, gummy worms, sour snakes, and more.
  • Chill Gummies - Chill gummies are more robust than its counterpart, the "Relax" gummy line. Chill Gummies are edible CBD gummies available in a wide variety of flavors, strengths, and styles including gummy bears, sour snakes, rainbow bites, watermelon slices, sour snakes, rainbow bites, peanut butter chocolate, ocean gummies, gummy worms, gummy rings and more.
  • CBD Liquid Gold - CBD Liquid Gold is derived from naturally grown industrial hemp plants, certified by USA labs and then carefully mixed with a patent-pending (non-PG) all-natural base formulation.
  • Blue CBD - Blue CBD Crystal Isolate is a high-end vapor liquid and oral drop infused with premium CBD rich hemp oil. CBD liquids are Premium Gold quality and test at a 7X higher concentration.
  • Relax Gummies - Relax Gummies give a lighter effect of CBD with some natural flavors in comparison to its counterpart Chill Gummies. Relax Gummies are perfect for anyone with a sweet tooth that's looking for a lighter effect without sacrificing quality or taste.
  • Premium Hemp Liquid Pet - CBD For Pets is a new and refreshing product from Diamond CBD for all the millions of pets out there. It is an organic product and also has unique flavors in it.
  • CBD Re-Leaf - Disposable, long-lasting, and ready to Use CBD Re-leaf vaping pens available in a variety of flavors. Easily take CBD anywhere on the go.
  • Relax Extreme CBD - Relax Extreme CBD Oil provides a high-quality, high-strength dose of CBD through oral drops. It is very easy to use and works instantly. Simply place a drop under the tongue. Available in various strengths.
  • CBD Double Shot - CBD Double Shots are specifically designed for one-time use. Easily squeeze the package in your mouth and swallow; it's that simple. Take it anywhere you go. Relaxation is now conveniently in your pocket. Drinkable CBD shots provide a quick boost of relaxation on the go. Available in various flavors.
  • Chill Pill - CBD infused capsules available in various strengths. Relax, take a Chill Pill.

Over 1.2 million people currently use cannabis, including CBD products, for medical application, including cancer, epilepsy, and depression. By sourcing hemp outside the U.S., the company avoids current federally-based legal problems involved in growing cannabis domestically. In the meantime, PotNetwork Holdings continues to target a large and rapidly developing cannabis market, expanding from $6.5 billion in 2016, to an expected $30 billion in 2021 (Forbes), and $50 billion in 2026 (Bloomberg). The cannabidiol market alone is projected to reach $2.1 billion in 2020, a 700% increase from 2015. PotNetwork Holdings Inc. plans to expand its subsidiaries as well as make strategic acquisitions. Disclaimer

PotNetwork Holdings Inc. Company Blog

PotNetwork Holdings Inc. News:

PotNetwork Holding, Inc. PCOAB Concludes Initial Auditing Requirement for Up-List

PotNetwork Holding, Inc. to Retire over 52% of Issued and Outstanding Common Shares

National Radio and Web Broadcast to Feature PotNetwork on R.P. Summit Business Hour on Tuesday, November 21, 2017

Medical Cannabis Payment Solutions (REFG)

The QualityStocks Daily Newsletter would like to spotlight Medical Cannabis Payment Solutions (REFG). Today, Medical Cannabis Payment Solutions closed trading at $0.07, up 1.45%, on 469,603 volumewith 50 trades. The stock’s average daily volume over the past 60 days is 460,710, and its 52-week low/high is $0.0161/$0.20.

Medical Cannabis Payment Solutions (OTC:REFG), the industry’s leading payment processing solution for the marijuana industry, announces that it has engaged the corporate communications expertise of NetworkNewsWire. "We have been working for a long time to improve our online presence, increase our transparency, and to provide our customers, partners, investors and the media the information they need to understand our best-in-class technology and solutions,” said company CEO Jeremy Roberts. “Our partnership with NetworkNewsWire will play an important role as we refine our communication strategies to efficiently meet these goals.”

Medical Cannabis Payment Solutions (REFG), headquartered in Cheyenne, Wyoming, is a first-tier merchant processing cannabis industry pioneer, offering one of the first and only comprehensive card processing operations of its kind to serve the state-sanctioned medical marijuana industry. The company's state of the art system, which also tracks sales and tax collection, and eliminates the need to deal in cash-only transactions.

Through its robust, closed-loop merchant processing system, the company's unique "StateSourced" proprietary system enables authorized operation under FinCEN parameters and complies with all regulatory frameworks. StateSourced is tailored to deliver full-spectrum merchant processing services, providing the convenience of modern commercial card processing resources and making it the first operation of its kind geared to the legal cannabis industry.

StateSourced is not a prepaid or gift card, which is an important variable for merchants since standard banking institutions have not offered this form of payment processing to the legal cannabis industry. Federal law still considers marijuana illegal under the Controlled Substances Act, although 29 states and the District of Columbia have legalized the plant either for medicinal or recreational uses or both. This restriction has kept financial institutions at bay since most banks are federally insured and haven't been inclined to venture into the nascent industry.

Medical Cannabis Payment Solutions is able to offer its StateSourced card on a state-by-state basis where the card can be used in purchasing product from a legal, authorized vendor, providing a much-needed option for consumers and businesses alike. In another first, the company is collaborating with First Bitcoin Capital Corporation to integrate First Bitcoin's cryptocurrency ($Weed) with Medical Cannabis Payment Solutions' StateSourced payment gateway. This collaboration will allow state-licensed marijuana establishments across the nation to accept both StateSourced debit cards and cryptocurrencies such as WeedCoin and Bitcoin.

Medical Cannabis Payment Solutions president and CEO Jeremy Roberts and his executive team are working with state lawmakers to introduce legislation in an effort to address the growing problems in banking for the medical cannabis industry. For companies in the emerging legal cannabis industry, where retail and non-retail transactions such as vendor payments and payroll are almost exclusively paid for with cash, the solutions offered by StateSourced can help businesses avoid the inherent risks associated with a cash-intensive sector. Medical Cannabis Payment Solutions has also signed its first StateSourced contract with a Las Vegas-based vertically integrated marijuana establishment.

"We've completed our transition from development stage to revenue stage," says Roberts. "We have just started our business development efforts and the market is responding very well. We anticipate having many more, similar releases."

Medical Cannabis Payment Solutions provides end-to-end management across multiple systems for medicinal marijuana operations. The company solves the fragmentation problem experienced by many of these rapidly growing companies by identifying tools that are important to dispensaries and customizing those tools to meet the specific needs of this unique industry. Disclaimer

Medical Cannabis Payment Solutions Company Blog

Medical Cannabis Payment Solutions News:

Medical Cannabis Payment Solutions (REFG) Engages NetworkNewsWire for Corporate Communications Solutions

Medical Cannabis Payment Solutions to Launch New Website and Portal, Completes Rebrand of its Product Offering

Medical Cannabis Payment Solutions (REFG) Integrates Cryptocurrency Payment Options

InMed Pharmaceuticals, Inc. (CSE:IN) (OTCQB:IMLFF)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals, Inc. (IMLFF). Today, InMed Pharmaceuticals, Inc. closed trading at $0.7542, off by 5.43%, on 1,799,055 volume with 1,114 trades. The stock’s average daily volume over the past 60 days is 878,965, and its 52-week low/high is $0.0981/$0.8611.

The discovery of the human body’s endocannabinoid system in the early 1990s led to a surge of new drug development activity to address multiple maladies and identify new ways to treat serious diseases. The pharma industry’s predominant focus has been on the most recognized and easiest-to-isolate plant-sourced cannabinoids THC (tetrahydrocannabinol) and CBD (cannabidiol). Despite their potential therapeutic efficacy, plant-sourced cannabinoid therapies have complex development limitations that impede effective use. Beyond economic constraints on production, inherent problems exist in ensuring the quality, purity and consistency requisite for serious pharmaceutical drug development. But InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) has initiated a scientific paradigm shift in discovering potential breakthrough cannabinoid-based therapies that advances far beyond basic cannabinoid production and the over-the-counter sales of oils and elixirs.

InMed Pharmaceuticals, Inc. (IMLFF) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company’s cannabinoid biosynthesis technology and drug development pipeline, serves as InMed’s fundamental value driver.

Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases, as well as a database on the structure of currently approved pharmaceutical products and an extensive database on over 90 individual cannabinoid drugs found in cannabis. This extensive collection of data is derived from both public and propriety-based sources. Leveraging this tool, the company aims to create associations between approved pharmaceuticals and cannabinoids with similar structures in order to identify active cannabinoids that have the potential to treat specific diseases. Per InMed’s website, this type of bioinformatics assessment represents “significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease.”

After discovering these promising active cannabinoids, InMed moves to test and confirm their activity in biological systems through in vitro and in vivo experimentation. It is at this stage of development that the company’s proprietary biosynthesis process of cannabinoid manufacturing will be most promising. InMed is currently developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. By modifying the agriculture-based formula for harvesting cannabinoids, InMed aims to combine the inherent safety and known efficacy of the natural drug structure with the convenience, control and quality of 21st Century laboratory-based manufacturing processes.

The company’s pipeline currently includes two drug candidates in preclinical development, including INM-750 for the treatment of epidermolysis bullosa (EB) and INM-085 for the treatment of glaucoma. Referred to by the Dystrophic Epidermolysis Bullosa Research Association of America as “The Worst Disease You’ve Never Heard Of,” EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. The condition currently has no approved treatment or cure. Through the development of INM-750, InMed is attempting to address this significant unmet medical need. The drug candidate replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.

INM-085, InMed’s second development candidate, is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease.

InMed is focused on progressing toward validation of its drug candidate selection, using data to secure its patents and developing key disruptive technologies. In 2016, the company was successful in completing financings of $1.9 million. In January 2017, InMed completed a non-brokered private placement of common shares generating aggregate gross proceeds of C$1.5 million, strongly positioning the company to attract the new investment required to fund its aggressive growth strategies in 2017.

The company’s management team has well over a century of combined experience in the biopharmaceutical space. Company CEO Eric Adams has more than 25 years of experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During his time as CEO of enGene Inc., he led the gene therapy startup to a position at the head of the industry.

Joining Adams on the InMed management team are Chief Scientific Officer Dr. Sazzan Hossain; Senior Vice President, Clinical and Regulatory Affairs Alexandra D.J. Mancini; SVP, Corporate Strategy & Investor Relations Chris Bogart; and Chief Financial Officer Jeff Charpentier, as well as Chief Medical Officer Dr. Ado Muhammed, MD, DPM, MFPM.

Muhammed, in particular, has an extensive history in the pharmaceutical industry, having previously served as an executive of GW Pharmaceuticals, a global leader in the development of cannabinoid-based medicines. During his time as Associate Medical Director of that company, Muhammed played an instrumental role in the development and FDA approval of one of the first cannabis drugs. This GW Pharmaceuticals development program coincided with a sharp rise in share price from less than $9 in 2013 to more than $129 today, with the company’s current market value totaling more than $2.9 billion. Disclaimer

InMed Pharmaceuticals, Inc. Company Blog

InMed Pharmaceuticals, Inc. News:

The Therapeutic Potential of Pharmacologically Active Cannabinoids

Advanced Biosynthesis Setting New Standards for Cannabinoid-based Pain Management

Purified Cannabinoids Open New Opportunities in Pain Management

AppSwarm, Inc. (SWRM)

The QualityStocks Daily Newsletter would like to spotlight AppSwarm, Inc. (SWRM). Today, AppSwarm, Inc. closed trading at $0.0858, up 41.72%, on 16,968,681 volume with 915 trades. The stock’s average daily volume over the past 60 days is 2,166,088 and its 52-week low/high is $0.002/$0.092.

AppSwarm, Inc. (SWRM) is a technology development and incubation acceleration company that partners up with developers through joint ventures, royalty agreements, marketing partnerships, and outright purchase agreements. Focusing on the ever-growing mobile applications market, the company provides all the resources needed for engagement, retention, virality and monetization.

The global games market generated approximately $100 billion in revenues in 2016, but large global game companies have made it extremely difficult for smaller developers to achieve success in the marketplace. As a result, many great ideas aren't monetized. AppSwarm solves this problem by providing the funding and critical business expertise needed to successfully launch and market new applications.

Business applications is another area of focus for the company. Targeting small to medium sized businesses, AppSwarm will be developing and acquiring mobile application tools and platforms that increase productivity and security via data encryption, cloud storage, content management and delivery, digital payments, automation, and customer loyalty marketing solutions. Recent acquisitions made so far represent only a small example of future planned initiatives to develop and market tools for the business community.

Regardless of the target market, AppSwarm can help developers accelerate the success of their app through funding, technology and marketing expertise, as well as a unique eco system that accelerates user acquisition. The company is able to assist at any state of development with completion of concept, market analysis, business and financial management, direct sales and marketing, social game development to ensure correct product application and expedient deployment with cost efficiency.

Ron Brewer, CEO of the company, has accumulated extensive leadership in the technology sector and brings valuable knowledge gained as a Director of Southbridge Advisory Group for nearly 20 years. Ron's C-level experience includes merger & acquisition and post-acquisition turnaround in both the private and small-cap public sector. John Rabbit, director of finance, is a seasoned business veteran that has worked with Fortune 500 firms and served in CEO, COO and CFO positions for firms ranking from $5 million to $300 million in annual revenues. John was directly involved in numerous acquisitions and served in executive capacities for several multinational subsidiaries.

With a well-suited management team, multiple synergistic revenue streams, and diversified growth strategy, AppSwarm is well positioned in a steadily growing industry with countless opportunities for capitalization. Disclaimer

AppSwarm, Inc. Blog

AppSwarm, Inc. News:

AppSwarm and SinglePoint Finalize Plans for Cannabis and Bitcoin Focused Applications and Technology

AppSwarm, Inc. (SWRM) and USA Real Estate Holding Company (USTC) Sign LOI to Launch Bitcoin Mobile Wallet

AppSwarm and SinglePoint Sign LOI to Conduct a Shared Roll-Out of Mobile Applications Specifically Geared to the Cannabis Industry

Global Payout, Inc. (GOHE)

The QualityStocks Daily Newsletter would like to spotlight Global Payout, Inc. (GOHE). Today, Global Payout, Inc. closed trading at $0.10524, up 20.69%, on 26,324,714 volume with 2,039 trades. The stock’s average daily volume over the past 60 days is 7,859,246, and its 52-week low/high is $0.009/$0.16.

Global Payout, Inc. (GOHE) provides comprehensive payment solutions that can be fully customized for virtually any domestic and international organization distributing money worldwide. The company is committed to enabling global access to technology for optimizing financial transactions and delivering a global financial eco-system with top-tier banking institutions and the highest level financial technology partnerships.

Today, more than ever before, commercial enterprises and government institutions need powerful financial technology solutions that have the flexibility to deliver innovative customer centric services and drive operational efficiency gains throughout the organization. The Global Reserve Platform is Global Payout's fully configurable "banking-in-a-box" web-based platform that can fulfill the front-to-back office processing requirements of domestic, foreign exchange and international payment service providers. This platform is designed to improve work flow, operational efficiencies, and global financial management for enterprises operating across the globe.

The Global Reserve Platform can manage practically any financial product, including core and traditional banking products, online banking, card management, mobile wallets, merchant payment processing, biometric payments and authentication management, bill payments and P2P payments, international remittances, government benefits management, loans management, FOREX, and SWIFT / ACH / SEPA payments. Powered by the Global Reserve Administrative module, the platform can be customized for enterprises across a multitude of business sectors.

Investment in financial technology (FINTECH) companies has grown dramatically in recent years with the role of today's banks shrinking and demand for improved financial solutions continuing to rise. As the industry has continued to expand rapidly, Global Payout's management team has directed its focus on identifying the most promising market sectors with FINTECH needs. The four core areas selected are logistics, small and medium enterprises (SME), banking and travel.

In 2015, Global Payout introduced MoneyTrac Technology Inc. as a majority owned subsidiary to more effectively focus on the development of financial technologies that specifically address many of the challenges that enterprises in a variety of alternative and "high-risk" market sectors are faced with in processing financial transactions. Powered by Virtu Network Solutions, the MoneyTrac Technology platform is one the most configurable and intuitive financial technology platforms available to alternative and "high-risk" enterprises and provides them with solutions that effectively manages everything from pin debit and virtual currency, to compliance and cash flow logistics.

With the global economy constantly becoming more diversified and connected, Global Payout is well positioned with the technology software solutions its team has developed to address many different needs worldwide. Management has committed itself to exploring and identifying every avenue possible for further establishing itself as a recognized leader in FINTECH solutions. Disclaimer

Global Payout, Inc. Company Blog

Global Payout, Inc. News:

CannabisNewsWire Announces Publication on Various Applications of Blockchain Technology

MoneyTrac Technology, Inc. Secures Revenue Opportunity with Definitive Referral and Consultant Partnership Agreement with GreenRush Group, Inc.

Bitcoin’s Rise Solidifies the Intersection of Cannabis and Cryptocurrency


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



(PTI) +161.28%


(GRCK) +53.33%


(AEPT) +45.45%

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251